Document is current
Any future updates will be listed below
-
Authors
Schade, Amy E.
Perurena, Naiara https://orcid.org/0000-0003-0874-3389
Yang, Yoona https://orcid.org/0000-0002-7446-8816
Rodriguez, Carrie L. https://orcid.org/0000-0002-6796-8054
Krishnan, Anjana
Gardner, Alycia https://orcid.org/0000-0003-2185-5174
Loi, Patrick https://orcid.org/0000-0001-8476-3803
Xu, Yilin https://orcid.org/0009-0002-5696-7475
Nguyen, Van T. M.
Mastellone, G. M.
Pilla, Natalie F. https://orcid.org/0000-0002-9971-3590
Watanabe, Marina
Ota, Keiichi
Davis, Rachel A.
Mattioli, Kaia
Xiang, Dongxi
Zoeller, Jason J. https://orcid.org/0000-0003-3531-2111
Lin, Jia-Ren https://orcid.org/0000-0003-4702-7705
Morganti, Stefania https://orcid.org/0000-0001-5284-9944
Garrido-Castro, Ana C. https://orcid.org/0000-0002-5989-6636
Tolaney, Sara M. https://orcid.org/0000-0002-5940-8671
Li, Zhe
Barbie, David A.
Sorger, Peter K. https://orcid.org/0000-0002-3364-1838
Helin, Kristian https://orcid.org/0000-0003-1975-6097
Santagata, Sandro https://orcid.org/0000-0002-7528-9668
Knott, Simon R. V.
Cichowski, Karen https://orcid.org/0000-0003-3940-3782
- License Information
-
More Information
Article History
Received: 3 June 2022
Accepted: 6 September 2024
First Online: 9 October 2024
Competing interests
: K.C. is an advisor at Genentech and serves on the scientific advisory board of Erasca. S.M.T. has consulting or advisory roles at Novartis, Pfizer, Merck, Lilly, Nektar, NanoString Technologies, AstraZeneca, Puma Biotechnology, Genentech/Roche, Eisai, Sanofi, Bristol Myers Squibb, Seattle Genetics, Odonate Therapeutics, OncoPep, Kyowa Hakko Kirin, Samsung Bioepis, CytomX Therapeutics, Daiichi Sankyo, Athenex, Gilead, Mersana, Certara, Chugai Pharma, Ellipses Pharma, Infinity, 4D Pharma, OncoSec Medical, BeyondSpring Pharmaceuticals, OncXerna, Zymeworks, Zentalis, Blueprint Medicines, Reveal Genomics and ARC Therapeutics; and received institutional research funding from Genentech/Roche, Merck, Exelixis, Pfizer, Lilly, Novartis, Bristol Myers Squibb, Eisai, AstraZeneca, NanoString Technologies, Cyclacel, Nektar, Gilead, Odonate Therapeutics, Sanofi and Seattle Genetics. P.K.S. is a co-founder and member of the BOD of Glencoe Software, member of the BOD for Applied Biomath, member of the scientific advisory board for RareCyte, NanoString and Montai Health, holds equity in Glencoe, Applied Biomath and RareCyte, consults for Merck, and has received research funding to the institution from Novartis and Merck in the past 5 years. A.C.G.-C. has grant/research funding to institution from Gilead Sciences, AstraZeneca, Daiichi-Sankyo, Merck, Zenith Epigenetics, Bristol-Myers Squibb, Novartis, Foundation Medicine and Biovica; serves as a consultant and member of the scientific advisory board for AstraZeneca, Daiichi-Sankyo and Novartis; has received honoraria from AstraZeneca and Daiichi-Sankyo; and has other financial or materials support from Roche/Genentech, Gilead Sciences, AstraZeneca, Novartis and Merck. K.H. is a consultant for and a co-founder of Dania Therapeutics Aps and a scientific advisor for Hannibal Health Innovation. S.R.V.K. is a founder and consultant at Faeth Therapeutics and Transomic Technologies. D.A.B. is a consultant for N of One/QIAGEN and Tango Therapeutics; is a founder and shareholder in Xsphera Biosciences; has received honoraria from Merck, H3 Biomedicine/Esai, EMD Serono, Gilead Sciences, Abbvie and Madalon Consulting; and has received research grants from BMS, Takeda, Novartis, Gilead and Lilly. The other authors declare no competing interests.
